Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Toronto-Dominion Bank (TD) Price & Performance

Neurocrine Biosciences IncTrade
Toronto-Dominion BankTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Toronto-Dominion Bank — how do they compare? Neurocrine Biosciences Inc trades at $152.18 (market cap $16.46B), while Toronto-Dominion Bank trades at $121.35 (market cap $200.48B). The key difference: Toronto-Dominion Bank is far larger — about 12.2× Neurocrine Biosciences Inc's market cap, and Toronto-Dominion Bank pays a 2.63% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXTD
Market Cap
$16.46B$200.48B
Sector
HealthFinancials
52-Week High
$185.50$124.80
52-Week Low
$123.10$72.85
Enterprise Value
$16.48B
Dividend Yield
2.63%

Returns comparison

Trailing returns across standard periods

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Toronto-Dominion Bank

Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.

Read more on TD